Bevacizumab angiogenesis inhibitors
systematic review meta-analysis network meta-analysis
 

Avastin      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

advanced breast cancer (metastatic)  

RIBBON-I (Robert) on top capecitabine, 2009     bevacizumab + capecitabinecapecitabine 1st line Low risk of bias suggesting -32%-15%
AVF2119g (Miller) cape, 2005   bevacizumab + capecitabinecapecitabine 2nd line Risk of bias suggesting-2%7%
RIBBON-2 (Brufsky), 2009     bevacizumav + CTCT alone 2nd line suggesting-22%-10%
AVADO (Miles) 15mg , 2009     bevacizumab + docetaxeldocetaxel 1st line HER-2 negative suggesting-31%-8%
AVADO (Miles) 7.5mg, 2010   bevacizumab + docetaxeldocetaxel 1st line HER-2 negative Low risk of bias negative-14%5%
Burstein, 2005   bevacizumab + methotrexatemethotrexatenegative
Martin bevacizumab, 2011     bevacizumab + paclitaxelpaclitaxel 1st line HER-2 negative Risk of bias negative-21%
E2100 (Miller), 2007      NCTbevacizumab + taxanestaxanes 1st line Risk of bias suggesting-44%-14%
RIBBON-I (Robert) on top Tax or anthra, 2009     bevacizumab + taxanestaxanes 1st line suggesting -23%3%

lung cancer (metastatic)  

Reck, 2010     bevacizumab -
Herbst, 2011     bevacizumab + erlotiniberlotinib alone -
Sandler, 2006     bevacizumabplatinum based CT -
Johnson, 2004     bevacizumabplatinum based CT -
Nishio, 2009   bevacizumabplatinum based CT -
Herbst, 2007     bevacizumabplatinum based CT -

renal-cell carcinoma (advanced)  

CALGB 90206, 2010         bevacizumab plus interferon alfainterferon alphasuggesting-29%-14%
AVOREN, 2007         bevacizumab plus interferon alfainterferon alphasuggesting-37%-14%
Yang, 2003       bevacizumabplaceboExploratory -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons